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Objective To describe the management and outcomes of placenta
accreta, increta, and percreta in the UK.
Design A population-based descriptive study using the UK
Obstetric Surveillance System (UKOSS).
Setting All 221 UK hospitals with obstetrician-led maternity units.
Population All women diagnosed with placenta accreta, increta,
and percreta in the UK between May 2010 and April 2011.
Methods Prospective case identification through the monthly
mailing of UKOSS.
Main outcome measures Median estimated blood loss, transfusion
requirements.
Results A cohort of 134 women were identified with placenta
accreta, increta, or percreta: 50% (66/133) were suspected to have
this condition antenatally. In women with a final diagnosis of
placenta increta or percreta, antenatal diagnosis was associated
with reduced levels of haemorrhage (median estimated blood loss
2750 versus 6100 ml, P = 0.008) and a reduced need for blood
transfusion (59 versus 94%, P = 0.014), possibly because
antenatally diagnosed women were more likely to have
preventative therapies for haemorrhage (74 versus 52%,
P = 0.007), and were less likely to have an attempt made to
remove their placenta (59 versus 93%, P < 0.001). Making no
attempt to remove any of the placenta, in an attempt to conserve
the uterus or prior to hysterectomy, was associated with reduced
levels of haemorrhage (median estimated blood loss 1750 versus
3700 ml, P = 0.001) and a reduced need for blood transfusion
(57 versus 86%, P < 0.001).
Conclusions Women with placenta accreta, increta, or percreta
who have no attempt to remove any of their placenta, with
the aim of conserving their uterus, or prior to hysterectomy,
have reduced levels of haemorrhage and a reduced need for
blood transfusion, supporting the recommendation of
this practice.
Keywords Abnormal placental adherence, haemorrhage, placenta
accreta/increta/percreta.
Please cite this paper as: Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta,
increta, and percreta in the UK: a population-based descriptive study. BJOG 2014;121:62–71.
Introduction
Three variants of abnormally invasive placentation are
recognised: placenta accreta, in which placental villi invade
the surface of the myometrium; placenta increta, in which
placental villi extend into the myometrium; and placenta
percreta, where the villi penetrate through the myometrium
to the uterine serosa and may invade adjacent organs,
such as the bladder. Placenta accreta, increta, or percreta is
associated with major pregnancy complications, including
life-threatening maternal haemorrhage, large-volume blood
transfusion, and peripartum hysterectomy.1,2 However,
limited data exist to guide the optimal management of
this condition. The existing literature consists predomi-
nately of case reports, and studies undertaken using retro-
spective review of medical records, over a number of
years in a single or small number of tertiary-care institu-
tions.3–6 Such studies have a number of limitations,
including limited generalisability and a lack of statistical
power.
The aims of this study were to prospectively identify a
national population-based cohort of women with placenta
accreta, increta, or percreta to describe the current manage-
ment of this condition in the UK, and the associated
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outcomes for women and their infants, in order to inform
future practice guidelines.
Methods
Cases included all women identified as having placenta
accreta, increta or percreta, defined as either placenta accre-
ta, increta, and percreta diagnosed histologically following
hysterectomy, or post-mortem, or an abnormally adherent
placenta, requiring active management, including conserva-
tive approaches where the placenta is left in situ. The UK
Obstetric Surveillance System (UKOSS) was used to iden-
tify cases on a national basis between 1 May 2010 and 30
April 2011.7 Every month, report cards were sent to nomi-
nated clinicians in each obstetrician-led maternity unit in
the UK, with a tick box to indicate the number of cases of
placenta accreta, increta, or percreta they had seen that
month. The clinicians were asked to return all cards, even
when they had ‘nothing to report’. Data collection forms
were then sent to the clinicians who reported a case to
confirm the diagnosis and request further information con-
cerning potential risk factors, management, and outcomes.
All data requested were anonymous, and up to five remind-
ers were sent if data collection forms were not returned.
Data were double-entered into a customised database.
Information on the women’s year of birth and expected
date of delivery was used to identify duplicate case reports,
and cases were reviewed to ensure that they met the case
definition.
A v2 test, Fisher’s exact test, or Wilcoxon rank sum test,
as appropriate, was used to compare the characteristics,
management, and maternal outcomes of the cases according
to whether they were suspected of having placenta accreta,
increta, or percreta antenatally, and whether an attempt was
made to remove any of the placenta around the time of
delivery. All analyses were carried out using STATA statistical
software 11 (StataCorp, College Station, TX, USA).
Results
During the study period, all 221 UK hospitals with obste-
trician-led maternity units contributed data to UKOSS
(100% participation) and notified 187 cases of placenta
accreta, increta, or percreta, 16 of which were subsequently
reported by clinicians as not being cases after all. Data
collection forms were received for 144 (84%) of the
remaining notified cases: ten were subsequently excluded
(four because they were duplicates, three because they deliv-
ered outside the study period, and three because they did not
meet the case definition), leaving a total of 134 confirmed
cases of placenta accreta, increta, or percreta in an estimated
798 634 maternities.8–10 This represents an estimated inci-
dence of 1.7 per 10 000 maternities (95% CI 1.4–2.0).
Diagnosis
Placenta accreta, increta, or percreta was suspected prior to
delivery in half of the women (66/133, 50%). Twenty-eight
(42%) of these women were diagnosed by ultrasound and
magnetic resonance imaging (MRI), 32 (48%) by ultra-
sound only, and six (9%) by MRI only. Table 1 shows the
ultrasound and MRI features that were noted. The majority
of the women who did not have placenta accreta, increta,
or percreta suspected antenatally presented with a difficult
or unsuccessful delivery of the placenta, either at vaginal or
caesarean delivery (52/65, 80%); other presentations included
antepartum haemorrhage (10/65, 15%) and uterine rupture
(2/65, 3%).
Women who had placenta accreta, increta, or percreta
suspected antenatally were more likely than those who did
not to be multiparous [98% (65/66) versus 84% (56/67),
P = 0.003], were more likely to have had a previous caesar-
ean delivery [98% (65/66) versus 72% (48/67), P < 0.001],
Table 1. Ultrasound/MRI features noted in women who had
placenta accreta, increta, or percreta suspected prior to delivery






Placental lacunae 21 (38)




Increased vascularity 6 (11)
Other 9 (16)
Number (%) of cases
suspected prior to
delivery, diagnosed
by MRI (n = 34)*
MRI features noted***
Uterine bulging 8 (29)
Heterogenous signal intensity within
placenta
6 (21)
Dark intraplacental bands 5 (18)
Focal interruptions to myometrial wall 10 (36)




*Percentage of individuals with complete data.
**A total of 46% (25/56) of cases diagnosed by ultrasound had
two or more ultrasound features noted.
***A total of 36% (10/28) of cases diagnosed by MRI had two
more MRI features noted.
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and were more likely to have had placenta praevia diag-
nosed prior to delivery [97% (64/66) versus 33% (22/67),
P < 0.001]. Sixty-three (95%) of the suspected cases had
both placenta praevia diagnosed antenatally and a previous
caesarean delivery, compared with 20 (30%) of the unsus-
pected cases (P < 0.001). Of the 20 unsuspected cases who
had both placenta praevia and a previous caesarean, one
was noted to have no features of morbidly adherent pla-
centa on ultrasound, and one was noted to have an uncer-
tain diagnosis at MRI; the remaining 18 did not appear to
have had imaging to specifically look for morbidly adherent
placenta.
There was also a suggestion that the women who had pla-
centa accreta, increta, or percreta suspected antenatally had a
greater severity of placental invasion, as they were more
likely to have a final diagnosis after delivery of placenta in-
creta or percreta, rather than accreta [43% (28/65) of sus-
pected cases versus 27% (18/67) of unsuspected cases,
P = 0.051]. No other significant differences were found
between the antenatally suspected and unsuspected women
in terms of the following characteristics: maternal age, eth-
nicity, socio-economic group, body mass index (BMI),
smoking status, gender of infant, or whether the women had
a multiple pregnancy, an IVF pregnancy, pregnancy inducted
hypertension or pre-eclampsia, other previous uterine sur-
gery, or previous uterine perforation (data not shown).
In total, 65% (87/133) of the women had a final diag-
nosis after delivery of placenta accreta, 5% (7/133) had a
final diagnosis of placenta increta, and 29% (39/133) had
a final diagnosis of placenta percreta. The final diagnosis
was based on a pathological examination of the uterus for
53% (68/129) of all cases: 48% (41/85) of the placenta ac-
creta cases, 86% (6/7) of the increta cases, and 57% (21/
37) of the percreta cases. Among women with a con-
firmed pathological diagnosis, 60% (41/68) of cases were
accreta, 9% (6/68) were increta, and 31% (21/68) were
percreta.
Management and outcomes of placenta accreta,
increta, and percreta
Figure 1 shows the cases of placenta accreta, increta, and
percreta according to whether they were suspected of hav-
ing this condition antenatally, whether an attempt was
made to remove any of the placenta around the time of
delivery, and whether a hysterectomy was subsequently per-
formed. The variety of therapies that were used to prevent
and/or treat haemorrhage in the cases is summarised in
Table 2. Women who had placenta accreta, increta, or per-
creta suspected antenatally were more likely than those
who did not to deliver by planned caesarean, have no
attempt to remove any of their placenta around the time of
delivery, have other therapy(ies) to prevent haemorrhage,
and be admitted to an intensive therapy unit (ITU)/
high-dependency unit (HDU) (Table 3). Although they
were less likely to have other therapy(ies) to treat haemor-
rhage, there was no significant difference in their median
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Figure 1. Placenta accreta, increta, or percreta cases, according to whether they were suspected of having this condition antenatally, whether an
attempt was made to remove any of the placenta around the time of delivery, and whether a hysterectomy was subsequently performed. *Does not
add up to total number of cases—data on whether placenta accreta/increta/percreta suspected antenatally missing for one woman. This woman had
an attempt to remove her placenta around the time of delivery and did not have a hysterectomy performed.
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estimated total blood loss, the proportion who received a
blood transfusion, or the proportion who subsequently had
a hysterectomy. Subgroup analysis, however, suggests that
although an antenatal diagnosis is not associated with a
lower median estimated total blood loss or need for blood
transfusion in women with a final diagnosis of placenta
accreta [median estimated blood loss 3000 ml (range 300–
14 435 ml) in suspected cases versus 3100 ml (range 200–
15 000 ml) in unsuspected cases, P = 0.9131; 84% (31/37)
of suspected cases had a blood transfusion versus 81% (39/
48) of unsuspected cases, P = 0.761], there is an association
in women who had a final diagnosis of placenta increta or
percreta [median estimated blood loss 2750 ml (range 250–
10 514 ml) in suspected cases versus 6100 ml (range 1500–
24 000 ml) in unsuspected cases, P = 0.008; 59% (16/27)
of suspected cases had blood transfusion versus 94% (17/
18) of unsuspected cases, P = 0.014].
A total of 102 (76%) of the women had an attempt
made to remove their placenta around the time of delivery.
Sixteen (16%) of these women were noted to have had part
(n = 12) or all (n = 4) of their placenta left in place after
the attempt. Fifty-eight hysterectomies were performed fol-
lowing an attempt to remove the placenta, five of which
were performed in women who had part and four of which
were performed in women who had their entire placenta
left after the attempt. Another 21 hysterectomies were per-
formed in women who had no attempt to remove any of
their placenta around the time of delivery. Although the
hysterectomy rate did not vary according to whether an
attempt was made to remove any of the placenta (Table 4),
there was a variation in when the hysterectomies were per-
formed: the 58 hysterectomies that followed an attempt to
remove the placenta all occurred within 24 hours of
delivery (31 known to have been performed within 1 hour
of delivery). By contrast, of the 21 hysterectomies that fol-
lowed no attempt to remove any of the placenta, 16 (76%)
were performed within 24 hours of delivery (14 known to
have been performed within 1 hour of delivery); the
remaining hysterectomies were performed a median of
51 days (range 6–97 days) after delivery because of exces-
sive vaginal bleeding in three cases, uncontrollable vaginal
bleeding following a later elective attempt at removal of the
placenta in one case, and after discussion with the woman
concerned in one case. Of the 11 women who had no
attempt to remove any of their placenta and did not
subsequently have a hysterectomy, nine (82%) were fol-
lowed up: the placenta was documented to have completely
resorbed in three of these women a median of 145 days
(range 134–156 days) after delivery, and six were still
awaiting complete resorption at the time of data collection.
Of the seven women who did not have a hysterectomy and
were noted to have had part of their placenta left after an
attempt to remove it, five (71%) were followed up: the pla-
centa was documented to have completely resorbed in four
of these women a median of 87.5 days (range 64–144 days)
after delivery, and one woman was still awaiting complete
resorption at the time of data collection.
Five of the women who had no attempt to remove any
of their placenta were treated with methotrexate: three of
these women were amongst those who subsequently had a
delayed hysterectomy, one was amongst those whose
placenta was documented to have completely resorbed, and
one was amongst those still awaiting complete resorption.
Of the women who were noted to have had part of their
placenta left in place after an attempt to remove it, two
were treated with methotrexate: both of these women were
Table 2. Therapies used to prevent and/or treat haemorrhage in women with placenta accreta, increta, or percreta
Therapy Number (%) of cases that had
therapy used to prevent
haemorrhage (n = 134)
Number (%) of cases that had
therapy used for treatment of
haemorrhage (n = 134)
Syntocinon bolus/IV/IM 12 (9) 4 (3)
Syntocinon infusion 57 (43) 44 (33)
Ergometrine 5 (4) 34 (25)
Prostaglandin F2a 1 (1) 38 (28)
Misoprostol 7 (5) 8 (6)
Intrauterine balloons 5 (4) 28 (21)
B-Lynch or other brace suture 0 (0) 18 (13)
Artery embolisation/balloon tamponade 22 (16) 11 (8)
Pelvic vessel ligation 6 (4) 5 (4)
Intra-abdominal packing 0 (0) 16 (12)
Recombinant activated factor VII 0 (0) 5 (4)
Other 4 (3) 15 (11)
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amongst those whose placenta was documented to have
completely resorbed.
As well as being more likely to have been diagnosed
antenatally, in terms of characteristics, women who had no
attempt to remove any of their placenta were more likely
than those who did to have had a previous caesarean
delivery [97% (31/32) versus 80% (82/102), P = 0.025],
were more likely to have had placenta praevia diagnosed
prior to delivery [88% (28/32) versus 57% (58/101),
P = 0.002], and were more likely to have a final diagnosis
of placenta increta or percerta, rather than accreta [71%
(22/31) versus 24% (24/102), P < 0.001]; no other signifi-
cant differences were found in other current pregnancy,
previous obstetric, or sociodemographic characteristics
(data not shown). Despite being more likely to have a
greater severity of placental invasion, the women who had
no attempt to remove any of their placenta were less likely
to have other therapy(ies) to treat haemorrhage, had a
lower estimated total blood loss, and were less likely to
have a blood transfusion (Table 4).
Although none of the women with placenta accreta,
increta, or percreta died, additional severe morbidity was
Table 3. Peripartum management and maternal outcomes by whether placenta accreta, increta, or percreta was suspected antenatally
Peripartum management/maternal outcome Number (%), unless otherwise
stated, of cases suspected
antenatally (n = 66)*
Number (%), unless otherwise
stated, of cases not suspected
antenatally (n = 67)*
P
Planned mode of delivery
Vaginal 2 (3) 20 (30) <0.001
Caesarean 64 (97) 46 (70)
Attempt made to remove any of placenta around time of delivery
No 27 (41) 5 (7) <0.001
Yes 39 (59) 62 (93)
Hysterectomy performed
No 23 (35) 31 (46) 0.18
Yes 43 (65) 36 (54)
Hysterectomy type
Total 25 (58) 18 (50) 0.469
Subtotal 18 (42) 18 (50)
Other therapy(ies) to prevent haemorrhage**
No 17 (26) 32 (48) 0.007
Yes 49 (74) 34 (52)
Other therapy(ies) to treat haemorrhage**
No 33 (50) 17 (25) 0.003
Yes 33 (50) 50 (75)
Median estimated total blood loss in ml (range) 3000 (250–14 435) 3500 (200–24 000) 0.126
Estimated total blood loss (ml)
<2500 30 (45) 20 (30) 0.063
2500 or more 36 (55) 47 (70)
Blood products given
No 17 (27) 10 (15) 0.109
Yes 47 (73) 56 (85)
Median units of whole or packed red cells transfused
(range)***
7 (0–24) 7 (2–29) 0.783
Median units of fresh frozen plasma transfused (range)*** 3.5 (0–13) 4 (0–12) 0.685
Median units of platelets transfused (range)*** 0 (0–6) 0 (0–4) 0.813
Median units of cryoprecipitate transfused (range)*** 0 (0–10) 0 (0–10) 0.848
Median ml of cell salvaged blood transfused (range)*** 75 (0–8000) 0 (0–1700) <0.001
Admission to ITU/HDU
No 13 (20) 29 (43) 0.003
Yes 53 (80) 38 (57)
Median duration of stay in ITU/HDU in days (range) 2 (1–26) 1.5 (1–19) 0.617
*Percentage of individuals with complete data.
**See Table 2.
***In women who received some type of blood product.
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noted in 18 (13%) of the women: ten had damage to their
bowel, urinary tract, or bladder (six were women who had
an attempt to remove their placenta and had a hysterec-
tomy within 24 hours of delivery, and four were women
who had no attempt to remove any of their placenta, three
of whom had a hysterectomy within 24 hours of delivery
and one of whom had a delayed hysterectomy); three had
sepsis (all three had an attempt to remove their placenta,
two of whom had a hysterectomy within 24 hours of deliv-
ery); three had a vesicovaginal fistula (two had an attempt
to remove their placenta and had a hysterectomy within
24 hours of delivery, and one had no attempt to remove
any of their placenta and had a hysterectomy within
24 hours of delivery); one had a uterocutaneous fistula that
eventually resolved spontaneously (this woman had no
attempt to remove any of her placenta and did not have a
hysterectomy); three had a thrombotic event; and two had
a cardiac arrest.
Four of the women lost or had their pregnancy termi-
nated before 24 weeks of gestation. The remaining 130
women gave birth to a total of 134 infants (126 singletons
and eight twins). Just over half (66/130, 51%) of these
women delivered prior to 37 weeks of gestation, the
majority (62/66, 94%) by caesarean: 70% (43/61) of the
Table 4. Peripartum management and maternal outcomes of women with placenta accreta, increta, or percreta, by whether an attempt made to




otherwise stated, of cases
who had no attempt to
remove placenta around
time of delivery (n = 32)*
Number (%), unless
otherwise stated, of cases
who did have an attempt
to remove placenta around
time of delivery (n = 102)*
P
Caesarean delivery
No 2 (6) 14 (14) 0.356
Yes 30 (94) 88 (86)
Hysterectomy peformed
No 11 (34) 44 (43) 0.379
Yes 21 (66) 58 (57)
Hysterectomy type
Total 12 (57) 31 (53) 0.771
Subtotal 9 (43) 27 (47)
Other therapy(ies) to prevent haemorrhage**
No 7 (23) 42 (42) 0.055
Yes 24 (77) 59 (58)
Other therapy(ies) to treat haemorrhage**
No 24 (75) 26 (26) <0.001
Yes 8 (25) 75 (74)
Median estimated total blood loss in ml (range) 1750 (200–15 000) 3700 (500–24 000) 0.001
Estimated total blood loss (ml)
<2500 18 (56) 32 (31) 0.011
2500 or more 14 (44) 70 (69)
Blood products given
No 13 (43) 14 (14) <0.001
Yes 17 (57) 87 (86)
Median units of whole or packed red cells transfused
(range)***
7 (3–24) 7 (0–29) 0.597
Median units of fresh frozen plasma transfused (range)*** 4 (0–13) 4 (0–12) 0.763
Median units of platelets transfused (range)*** 0 (0–4) 0 (0–6) 0.583
Median units of cryoprecipitate transfused (range)*** 0 (0–4) 0 (0–10) 0.402
Median ml of cell salvaged blood transfused (range)*** 0 (0–8000) 0 (0–5500) 0.067
Admission to ITU/HDU
No 10 (31) 32 (31) 0.99
Yes 22 (69) 70 (69)
Median duration of stay in ITU/HDU in days (range) 1.5 (1–26) 2 (1–19) 0.894
*Percentage of individuals with complete data.
**See Table 2.
***In women who received some type of blood product.
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caesarean deliveries performed preterm were carried out as
an elective procedure (grade 3 and 4 urgency11) at a med-
ian of 35 weeks of gestation (range 27–36 weeks of gesta-
tion), and 30% (18/61) as an emergency (grade-1 or -2
urgency11) at a median of 31.5 weeks of gestation (range 24–
36 weeks of gestation). The indication for the majority (14/
18, 78%) of these emergency caesarean deliveries was ante-
partum haemorrhage (10/14, 71% had placenta praevia diag-
nosed antepartum). There were no stillbirths and two early
neonatal deaths amongst the 134 infants, equating to a peri-
natal mortality rate of 14.9 per 1000 (95% CI 1.8–52.8).
Although this was double the national rate of 7.5 per 1000,12
the difference was not statistically significant (RR 2.0, 95%
CI 0.5–7.8), noting the limited statistical power of this com-




This prospective population-based study has two main
findings. Firstly, in women with a final diagnosis of pla-
centa increta or percreta, antenatal diagnosis is associated
with reduced levels of haemorrhage and a reduced need for
blood transfusion. Secondly, making no attempt to remove
any of the placenta, either in an attempt to conserve the
uterus or prior to hysterectomy, is associated with reduced
levels of haemorrhage and a reduced need for blood trans-
fusion.
Strengths and weaknesses
A major strength of our study is its prospective popula-
tion-based design, not relying on routinely coded data to
ascertain cases. In order to fully capture all cases of placenta
accreta, increta, and percreta, including cases managed con-
servatively, we used a case definition that included clinically
as well as pathologically defined cases. We cannot therefore
be certain that all cases would have been pathologically con-
firmed; however, we restricted the inclusion of clinically
defined cases to those requiring active management. It is
thus unlikely that significant numbers of false-positive cases
have been included. Another potential limitation is that we
cannot be certain that we have ascertained all cases, despite
the presence of several reporting clinicians in each hospital,
and the active monthly nature of UKOSS case reporting.
However, previous studies using UKOSS have suggested
high rates of ascertainment.13,14 Importantly, we have no
evidence of a systematic bias in case ascertainment that may
affect the validity of our results.
Interpretation
Antenatal diagnosis of placenta accreta, increta, or percreta
allows for early delivery planning, including the availability
of a multi-professional team, discussion of the surgical
approach to delivery, preparation for invasive management,
including hysterectomy if necessary, as well as ensuring suf-
ficient blood products and other supporting therapies are
readily available.15 In women with a final diagnosis of pla-
centa increta or percreta, we found that an antenatal diag-
nosis is associated with reduced levels of haemorrhage and
a reduced need for blood transfusion. This association may
be the result of observed differences in the management of
antenatally diagnosed and undiagnosed women: women
diagnosed antenatally in our study were more likely than
those without antenatal suspicion to have preventative
therapies for haemorrhage, and were less likely to have an
attempt to remove their placenta. Regardless, our study
also demonstrates that more than half of women with pla-
centa accreta, increta, or percreta have a hysterectomy;
early diagnosis will allow for the appropriate planning of
anaesthetic and surgical resources in the event this is
required, and adequate counselling of the women involved.
The study shows that currently placenta accreta, increta,
and percreta is not diagnosed antenatally in half of cases,
and that 30% of undiagnosed cases have a prior caesarean
delivery as well as placenta praevia, a group with a high
incidence of the condition (around one in every 20
women).16 Ultrasound features such as placental lacunae,15
and MRI features such as uterine bulging,17 have been doc-
umented as being suggestive of placenta accreta, increta,
and percreta. Our study only collected information on the
antenatally suspected cases that were confirmed pathologi-
cally or clinically, so we cannot evaluate the reliability of
such features for diagnosing placenta accreta, increta, or
percreta; however, previous studies suggest that currently
there is no completely sensitive and specific antenatal diag-
nostic technique for the condition.15 In view of this, there
is an argument for managing the delivery of very high risk
women, such as those with a prior caesarean delivery and
placenta praevia, as if they have a morbidly adherent
placenta.
Debate remains over the optimal management of
placenta accreta, increta, and percreta: if the placenta fails
to separate after delivery, leaving it in place and proceeding
with either a hysterectomy or conservative management,
rather than trying to separate it, is currently recommended
by the Royal College of Obstetricians and Gynaecologists
(RCOG)18; the American College of Obstetricians and
Gynecologists19 currently make no specific recommenda-
tions regarding attempted placental separation. Our study
supports the RCOG recommendation, with the finding that
making no attempt to remove any of the placenta around
the time of delivery, in an attempt to conserve the uterus
or prior to hysterectomy, is associated with reduced levels
of haemorrhage and a reduced need for blood transfusion.
We did not observe any significant differences between the
68 ª 2013 RCOG
Fitzpatrick et al.
characteristics of women who did and did not have an
attempt to remove their placenta that could have offered
an alternative explanation for this association. Our study
suggests that currently only around a quarter of women
with placenta accreta, increta, or percreta have no attempt
to remove their placenta. Given the limitation of antenatal
diagnosis with the possibility of false positives, however,
there may be a case for gently trying to remove the pla-
centa before proceeding with a hysterectomy, when there
are no obvious signs of placental invasion.
Conservative management of placenta accreta, increta,
and percreta, involving leaving the placenta in place around
the time of delivery, with the aim of preserving the uterus,
is particularly contentious. One of the largest studies
(n = 167) to have examined maternal outcome after con-
servative treatment of placenta accreta, increta, and percre-
ta suggested that conservative management can preserve
the uterus in 78.4% of women, with a severe maternal
morbidity rate of 6%.20 In a recent follow-up study, the
same authors concluded that a women’s subsequent fertility
or obstetric outcome does not appear to be compromised
by uterine preservation following placenta accreta, increta,
or percreta.21 However, the authors suggest that women
should be advised of the high risk of recurrence in subse-
quent pregnancies.
Only 16 women in our study appear to have had no
attempt to remove their placenta, in a clear attempt to pre-
serve their uterus. Although preservation of the uterus suc-
ceeded in 11 (73%) of these women, five underwent
hysterectomy a median of 51 days (range 6–97 days) after
delivery: in four of these women this was because of exces-
sive vaginal bleeding. This highlights one of the concerns
about conservative management: that women may continue
to be at risk of severe bleeding for several months after
delivery. Another concern about conservative management
is that it may increase a woman’s risk of infection. Sepsis
was only noted in three women in our study, none of
whom were managed conservatively; however, the small
number of women managed conservatively makes it impos-
sible to infer that there is a genuinely low risk of sepsis,
and further research is needed to address this. Similarly,
very few women were managed with methotrexate: we thus
have no clear evidence of any added benefit of using this
approach.
Conclusion
In women with a final diagnosis of placenta increta or
percreta, an antenatal diagnosis is associated with reduced
levels of haemorrhage and a reduced need for blood
transfusion, possibly because antenatally diagnosed women
are more likely to have preventative therapies for haem-
orrhage, and are less likely to have an attempt made to
remove their placenta. Additionally, more than half of
women with placenta accreta, increta, or percreta have a
hysterectomy; early diagnosis will allow for the appropri-
ate planning of anaesthetic and surgical resources in the
event this is required, as well as adequate counselling of
the women involved. However, many cases of placenta
accreta, increta, and percreta are currently not diagnosed
antenatally, despite the presence of risk factors. Further
research is needed to establish the most sensitive and
specific antenatal diagnostic techniques. Women with pla-
centa accreta, increta, or percreta who have no attempt
to remove any of their placenta, with the aim of conserv-
ing their uterus, or prior to hysterectomy, have reduced
levels of haemorrhage and a reduced need for blood
transfusion, supporting policies that recommend this
practice.
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Commentary on ‘The management and outcomes of placenta
accreta, increta, and percreta in the UK: a population-based
descriptive study’
Placenta accreta spectrum (including accreta, increta, and percreta) is one of the scariest conditions that obstetricians
will face. As a relatively infrequent condition, most data regarding placenta accreta are derived from small retrospective
case series obtained in single institutions. Thus, the optimal management remains uncertain. In this issue of BJOG, Fitz-
patrick and colleagues report on 134 women with placenta accreta spectrum in a prospective population-based study in
the UK, confirming the dramatic morbidity associated with the condition. Importantly, they noted that antenatal diag-
nosis was associated with reduced levels of haemorrhage and a reduced need for blood transfusion. Another key observa-
tion was that women who had a hysterectomy with no attempt to remove the placenta experienced reduced
haemorrhage and a lower rate of blood transfusion than those for whom placental removal was attempted. This is espe-
cially impressive, as women with no attempt at placental removal had more severe placental invasion than those with
attempts at placental removal.
These findings underscore the importance of antenatal diagnosis. In the current study, only 50% of cases were
diagnosed antenatally. Strikingly, 20 of the unsuspected cases had BOTH a previous caesarean delivery and a previous
placenta praevia. Such risk factors should prompt clinicians to refer women for evaluation and counselling for possible
placenta accreta. In addition to avoiding placental removal, antenatal diagnosis allows for the use of other strategies
intended to minimise haemorrhage. Indeed, maternal outcomes are improved when delivery occurs in a tertiary care
centre with a multidisciplinary team experienced in the management of placenta accreta (Eller et al., Obstet Gynecol
2011;117:331–337).
The rate of placenta accreta in this population-based study was 1.7 per 10 000 maternities, which is considerably
lower the rates noted in recent US studies. This may be because of the historically lower rate of caesarean delivery in the
UK compared with the US. As the rate of caesarean delivery in the UK has been increasing, it will be of interest to see
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whether the rate of accreta increases as well. Hopefully the UK Obstetric Surveillance System (UKOSS) used in the
current study will provide such data. Also, it is crucial to investigate the possibility that differences in caesarean tech-
niques in the UK and US contribute to different rates of accreta.
We congratulate Drs Fitzpatrick and colleagues for their important contribution to our understanding of the accreta
spectrum. Clinicians should be alert to risk factors for accreta and refer such women for antenatal evaluation and coun-
seling. Ideally, women with suspected accreta should undergo scheduled delivery in a centre with expertise and experi-
ence in the management of accreta. In most cases, patients should have a planned caesarean hysterectomy, with no
attempts at placental removal. Having a well-stocked blood bank is a must. In addition, there are numerous unanswered
questions regarding the optimal management of accreta. It is only through more prospective multicentre efforts such as
that completed by the UKOSS that we will successfully decrease the morbidity of placenta accreta. Finally, these data
illustrate the need to redouble our work to safely reduce caesarean delivery rates.
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